Eric Sarin

The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023.

The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023.

The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023.

The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023.

The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023.